Big Pharma sign deals worth $7 billion with one tiny stock

Talk about putting your money where your mouth is...

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

AI Saves 82-Year-Old After Chemo Failed 6 Times Rachel Gearhart | Publisher | The Oxford Club Dear Reader, Check out this amazing story. It involves an 82-year-old named Paul with blood cancer. Paul went through six separate rounds of chemo… And all six failed. Then, a new company used AI to designate a new treatment for him. Two years later… Paul was cancer-free. It's one of the most important and astonishing scientific breakthroughs of our time. And now… the small company behind the breakthrough is signing massive deals with big pharma. Up to $674 million with Merck… $1.2 billion with Bristol Myers Squibb… and up to an astonishing $5.2 billion to develop 15 potential treatments with Sanofi. We're talking about up to $7 billion worth of deals for a company that's worth a fraction of that amount. The stock trades for less than $10 today. But it might just become the #1 AI company in the world over the next few years. Go here to see the full story. Good investing, Rachel P.S. The same man who called 4 of the top 6 stocks in the markets from 2000 to 2020, is naming this his #1 stock going forward. He explains why here. You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. To stop receiving special invitations and offers from Wealthy Retirement, please click here. Please note: This will not impact the fulfillment of your subscription in any way. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement © 2023 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 1.800.589.3430 | International: +1.443.353.4334 | Fax: 1.410.329.1923 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.